You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes

    SBC: BIONIKS            Topic: NIAMS

    DESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government